Akebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to BuyZolmax • 16 days ago
Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) was upgraded by equities research analysts at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on...
Share to Feed
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass...
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akebia Therapeutics (AKBA Research Report) and Precision BioSciences...
Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) had its target price boosted by HC Wainwright from $5.00 to $6.00 in a research note issued on Thursday, Benzinga reports. The firm currently has...
Akebia Receives FDA Approval of Vafseo (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis Akebia Receives FDA Approval of Vafseo (vadadustat...
Akebia Therapeutics (AKBA) has provided an update. Akebia Therapeutics, Inc. has made a significant stride in the healthcare market with the FDA's...
Akebia Therapeutics (NASDAQ:AKBA Get Free Report) had its price target boosted by analysts at HC Wainwright from $5.00 to $6.00 in a research report issued on Thursday, Benzinga reports. The...
The FDA-approved Vafseo tablets by Akebia Therapeutics for managing anemia in adult dialysis patients with chronic kidney disease. Learn about its once-daily oral HIF-PH inhibitor and global approval...
Akebia Therapeutics, Inc. (NASDAQ:AKBA Get Free Report) saw some unusual options trading activity on Tuesday. Investors acquired 2,369 put options on the company. This represents an increase...
Akebia Therapeutics (NASDAQ:AKBA Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting...